Press Release

Cambridge, Mass. (August 17, 2021) – Remix Therapeutics, a biotechnology company developing small molecule therapies designed to reprogram RNA processing and address the underlying drivers of disease, today announced that Peter Smith, PhD, Co-Founder, President and Chief Scientific Officer of Remix, has been appointed President and Chief Executive Officer. Smith and Kevin Bitterman, PhD, partner at Atlas Venture, co-founded Remix in 2019 with a vision to invent a new class of medicines to address unmet medical needs.   The company was seeded in 2019 with $16M from Atlas Venture and The Column Group. Later in 2020, Remix closed a $67M Series A financing led by Foresite Capital, with participation from Atlas Venture, The Column Group, Arch Venture Partners, Casdin Capital and Alexandria Venture Investments.

“It is my pleasure to congratulate Pete on his promotion to CEO at Remix,” said Matt Patterson, Executive Chairman of the Board of Directors. “Pete has built an extraordinary team and we have full confidence in his leadership as Remix works to turn the unique potential of RNA processing into powerful therapeutic solutions for patients.”

Before founding Remix, Peter was Chief Scientific Officer at H3 Biomedicine, where his team introduced several molecules into clinical trials with precision medicine approaches to treat various cancers. Prior to H3 Biomedicine, he held various positions at Millennium/Takeda, where he focused on oncology drug discovery and early clinical development. He received his doctorate in Cancer Pharmacology and Drug Development from Newcastle University and completed a postdoctoral fellowship at Dana Farber Cancer Institute.

“I would like to thank the Board and the entire Remix team for this incredible opportunity,” said Smith. “It has been a privilege to work alongside this talented team and I look forward to continuing to drive Remix’s progress in this new role. We remain committed to enhancing our REMaster platform as well as advancing a pipeline of novel oral small molecule therapies to the clinic. I’m thrilled to be able to lead Remix through this next phase of innovation and to bring new medicines to patients.”

# # #

About Remix Therapeutics
Remix Therapeutics is a biotechnology company developing novel small molecule therapies designed to reprogram RNA processing and treat disease in entirely new ways. The REMaster technology platform makes it possible to identify patterns in RNA processing and exploit them to modulate gene expression. Our innovative therapeutic approach has the ability to alter the way genes are read from the genome, to correct, enhance, or eliminate the gene message, thereby addressing disease drivers at their origin. For more information visit, remixtx.com.

Media Contact:

Lissette Steele
lsteele@vergescientific.com
202.930.4762 ext. 409

Cambridge, Massachusetts. (March 16, 2021) – Remix Therapeutics, a biotechnology company developing small molecule therapies designed to reprogram RNA processing and address the underlying drivers of disease, today announced the appointment of Matthew R. Patterson as Executive Chairman of the company’s Board of Directors. Mr. Patterson is the co-founder and former chairman and CEO of Audentes Therapeutics, a gene therapy company acquired by Astellas Pharma in 2020.

“Matt has had an impressive 30-year career in research, drug development, and the commercialization of innovative therapeutics for both private and publicly held biotechnology companies,” said Kevin Bitterman, PhD, Founding Chairman of the Board of Remix Therapeutics and Partner at Atlas Venture. “His knowledge of the industry and experience building and advancing early-stage companies will be invaluable as we shape the path forward for Remix.”

“We are thrilled to have Matt play an active role in defining and executing against a sharply focused business plan for Remix,” adds Pete Smith, PhD, Co-Founder, President and CSO of Remix Therapeutics and Atlas Venture Entrepreneur in Residence. “His experience with corporate development will broaden our organizational capabilities as we enhance our proprietary REMaster technology platform and advance our lead programs into the clinic.”

Mr. Patterson is currently Strategic Advisor for Audentes Therapeutics. He co-founded and led the company from 2013 until its sale to Astellas in 2020. Prior to Audentes, Mr. Patterson was an Entrepreneur-In-Residence with OrbiMed and held senior roles at Amicus Therapeutics, BioMarin Pharmaceutical. and Genzyme Corporation. Mr. Patterson serves on several boards, including Homology Medicines, Inc., Vor Biopharma, Inc., 5:01 Acquisition Corporation, and the Alliance for Regenerative Medicine (ARM).

“I’m extremely excited to work with the Remix team and believe their focus on RNA processing offers an intriguing and promising way to pursue currently undruggable targets,” said Mr. Patterson. “The tremendous progress they’ve achieved in building REMaster, identifying new chemical matter, and advancing a pipeline of novel oral small molecule therapies is a testament to the expertise and dedication of the team. I’m looking forward to working with Remix leadership and the Board to realize the potential of RNA processing to deliver real therapeutic solutions for patients.”

# # #

About Remix Therapeutics

Remix Therapeutics is a biotechnology company developing novel small molecule therapies designed to reprogram RNA processing and treat disease in entirely new ways. Our REMaster technology platform allows us to identify patterns in RNA processing and exploit them to modulate gene expression. Our innovative therapeutic approach has the ability to alter the way genes are read from the genome, to correct, enhance, or eliminate the gene message, thereby addressing disease drivers at their origin. For more information visit, remixtx.com.

Media Contact:

Lissette Steele

lsteele@vergescientific.com

202.930.4762 ext. 409

Cambridge, Massachusetts. (December 8, 2020) – Remix Therapeutics, a biotechnology company developing small molecule therapies designed to reprogram RNA processing to address the underlying drivers of disease, launched today with $81 million in financing. The funds will support development of the company’s REMaster technology platform and advancement of a pipeline of RNA processing targeted therapeutics. The Series A round was led by Foresite Capital with participation from seed investors Atlas Venture and The Column Group. Additional investors joining the financing included Arch Venture and Alexandria Venture Investments.

“As we reach the limits of what is easily druggable with protein targeting therapies, reprogramming RNA processing represents an exciting new therapeutic opportunity. We believe we can precisely target the cellular complexes that process RNA to address the underlying drivers of disease, working upstream of protein expression,” said Pete Smith, PhD, Co-Founder, President and CSO of Remix Therapeutics and Atlas Venture Entrepreneur in Residence. “Backed by world-class investors, a distinguished board of directors and experts in the field, the Remix team is united in its singular focus to deliver new and better ways to treat disease, especially those with limited treatment options.”

While protein dysfunction is often the direct cause of disease, the root of that dysfunction often begins in a person’s genetic code with changes in DNA and subsequent RNA expression. Remix is designing medicines that target RNA processing to fine-tune how new RNA sequences are produced. These are small molecule therapies designed to be taken orally, allowing for therapeutic modulation throughout the body, including the central nervous system (CNS). Targeting RNA processing has the potential to address a broad range of diseases, including cancers, CNS diseases, rare diseases, and more.

“Remix is harnessing advances in data science, structural biology and chemistry to tackle disease in new and exciting ways,” said Michael Rome, PhD, Managing Director of Foresite Capital. “We believe the company is well-positioned to realize the potential of targeting RNA processing to deliver real therapeutic solutions for patients.”

Fueled by its proprietary REMaster technology platform, Remix is leveraging the power of data analytics, bespoke high-throughput screening technologies, and next generation chemistry to advance a pipeline of breakthrough therapies. The company’s innovative approach has the unique ability to precisely identify and target RNA processing steps to enhance or eliminate protein function, or to correct dysregulation in disease.

“RNA has long been considered a prime therapeutic target, but its innate complexities have made it notoriously difficult to drug. By focusing on RNA processing, the Remix team has identified a compelling way to pursue previously undruggable disease targets,” said Kevin Bitterman, PhD, Chairman of the Board of Remix Therapeutics and Partner at Atlas Venture.

Remix’s Board of Directors include:

· Kevin Bitterman, PhD, Chair of Remix Therapeutics, and Partner at Atlas Venture

· Michael Rome, PhD, Managing Director of Foresite Capital

· Leon Chen, PhD, Partner at The Column Group

· Scott Biller, PhD, Independent Board Member

· Peter Smith, PhD, President and CSO, Remix Therapeutics

· Kristina Burrow, Managing Director, Arch Venture, Board Observer

About Remix Therapeutics

Remix Therapeutics is a biotechnology company developing novel small molecule therapies designed to reprogram RNA processing and treat disease in entirely new ways. Our REMaster technology platform allows us to identify patterns in RNA processing and exploit them to modulate gene expression. Our innovative therapeutic approach has the ability to alter the way genes are read from the genome, to correct, enhance, or eliminate the gene message, thereby addressing disease drivers at their origin. For more information visit, remixtx.com.

About Foresite Capital

Foresite Capital funds visionary healthcare entrepreneurs. With approximately $3 billion in assets under management, Foresite Capital has a team of clinical scientists, engineers, analysts and partners who support and guide companies at all stages of their life cycles. The firm is headquartered in San Francisco with an office in New York. For more information visit www.foresitecapital.com.

About Atlas Venture

Atlas Venture is a leading biotech venture capital firm. With the goal of doing well by doing good, Atlas have been building breakthrough biotech startups for over 25 years, working side by side with exceptional scientists and entrepreneurs to translate high impact science into medicines for patients. Their seed-led venture creation strategy rigorously selects and focuses investment on the most compelling opportunities to build scalable businesses and realize value. For more information, please visit www.atlasventure.com.

About The Column Group

The Column Group is a leading venture capital firm based in San Francisco that seeks to partner with exceptional scientific founders, entrepreneurs, executives, and investment organizations with a shared vision for building the next generation of drug discovery and development companies. TCG invests in disease-focused drug discovery companies with the potential to become leaders in their respective fields. These companies are strongly supported by the unique and complementary skill sets of TCG’s team, which includes prominent authorities in the scientific, operational, and financial arenas.

Media Contact:

Lissette Steele

lsteele@vergescientific.com

202.930.4762 ext. 409